Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin

Roberto P. Santos; Pablo J. Sánchez; Asuncion Mejias; Daniel K. Benjamin; Thomas J. Walsh; Sanjay Patel; Hasan S. Jafri

doi:10.1097/01.inf.0000258698.98370.89

Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin

Roberto P. Santos, Pablo J. Sánchez, Asuncion Mejias, Daniel K. Benjamin, Thomas J. Walsh, Sanjay Patel, Hasan S. Jafri

Pediatrics

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.

Original language	English (US)
Pages (from-to)	364-366
Number of pages	3
Journal	Pediatric Infectious Disease Journal
Volume	26
Issue number	4
DOIs	https://doi.org/10.1097/01.inf.0000258698.98370.89
State	Published - Apr 2007

Keywords

Liposomal amphotericin B
Micafungin
Pharmacokinetic
Preterm infant
Primary cutaneous aspergillosis
Voriconazole

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Microbiology (medical)
Infectious Diseases

Access to Document

10.1097/01.inf.0000258698.98370.89

Cite this

@article{935b75501d554dc98bc9982266177d03,

title = "Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin",

abstract = "Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.",

keywords = "Liposomal amphotericin B, Micafungin, Pharmacokinetic, Preterm infant, Primary cutaneous aspergillosis, Voriconazole",

author = "Santos, {Roberto P.} and S{\'a}nchez, {Pablo J.} and Asuncion Mejias and Benjamin, {Daniel K.} and Walsh, {Thomas J.} and Sanjay Patel and Jafri, {Hasan S.}",

note = "Funding Information: This work was supported by the National Institute of Child Health and Human Development grant HD046000 and the Pediatric Pharmacology Research Unit Network (to HSJ) and grant 1U10-HD45962-02 (to DKB). ",

year = "2007",

month = apr,

doi = "10.1097/01.inf.0000258698.98370.89",

language = "English (US)",

volume = "26",

pages = "364--366",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin

AU - Santos, Roberto P.

AU - Sánchez, Pablo J.

AU - Mejias, Asuncion

AU - Benjamin, Daniel K.

AU - Walsh, Thomas J.

AU - Patel, Sanjay

AU - Jafri, Hasan S.

N1 - Funding Information: This work was supported by the National Institute of Child Health and Human Development grant HD046000 and the Pediatric Pharmacology Research Unit Network (to HSJ) and grant 1U10-HD45962-02 (to DKB).

PY - 2007/4

Y1 - 2007/4

N2 - Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.

AB - Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.

KW - Liposomal amphotericin B

KW - Micafungin

KW - Pharmacokinetic

KW - Preterm infant

KW - Primary cutaneous aspergillosis

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=34247105269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247105269&partnerID=8YFLogxK

U2 - 10.1097/01.inf.0000258698.98370.89

DO - 10.1097/01.inf.0000258698.98370.89

M3 - Article

C2 - 17414408

AN - SCOPUS:34247105269

SN - 0891-3668

VL - 26

SP - 364

EP - 366

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 4

ER -

Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this